Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy

Describes fundamental aspects of efflux pumps of the ATP-binding cassette superfamily, along with strategies to target and improve chemotherapy efficacy

Alejandro Sosnik (Volume editor), Reina Bendayan (Volume editor)

9780128164341

Hardback, published 13 November 2019

394 pages
23.4 x 19 x 2.6 cm, 0.97 kg

"The therapeutic success of antineoplastic drugs is a challenge due to the development of chemoresistance by the cancer cells. An understanding of the mechanism of chemoresistance and chemo-sensitization is critical to improving cancer treatment outcomes. Contributed by many experts around the world, this book offers up-to-date information on the efflux transporters and possible strategies to inhibit the efflux pumps in cancer cells. There are several books in the marketplace related to chemoresistance and chemo-sensitization. This book, however, focuses on the mechanistic approach to characterization and inhibition of efflux transporters. Thus, it is expected to be well received by the scientists working in this field of study." --Doody

Approx.378 pages

1. Introduction2. Efflux transporters in cancers resistance: Molecular and functional identification and characterization of P-glycoprotein3. Efflux transporters in cancers resistance: Molecular and functional identification and characterization of Multidrug Resistance Proteins4. Efflux transporters in cancers resistance: Molecular and functional identification and characterization of breast cancer resistance protein5. Molecular imaging of the activity of membrane efflux transporters in cancer6. Endocrine cancers7. Hematologic cancers8. Gastrointestinal cancers9. Musculoskeletal cancers10. Lung cancers11. Skin cancers12. Cancers of the central nervous system13. Cancer stem cells14. Blood-brain barrier and CNS tumors15. Nanomedicines to overcome efflux transporter-mediated resistance in cancer16. Pluronic®: The first nanomedicine ABC inhibitor translated into the clinics17. Cancer therapy with antibody-linked conjugates and MDR expression

Subject Areas: Personal & public health [MBNH], Biotechnology industries [KNDH1]